Additionally, because upregulation of MCL1 has been demonstrated to be involved in venetoclax resistance, the direct MCL1 antagonist AMG-176 has been shown to selectively kill CLL cells and act synergistically with venetoclax in vitro [139]. The gene discussed is MCL1; the disease is B-cell chronic lymphocytic leukemia.